Expect the sp to pick up from now on, especially on positive news.
Now the element of uncertainty over BioMoti has been removed we have more clarity over what the company is aiming to accomplish. Jim Millen has surely not been sitting on his hands since joining PYC and will have ideas for new contracts with the accent on profitability.
Importantly the Val201 phase 1/11 trial (hormone resistant prostate cancer) is also progressing smoothly with no adverse events, its cohort has been expanded to include less severely ill patients, and it is expected to report as scheduled. PYC will benefit both financially and reputationally from this if it is successful.
Hi Draey, I feel the same Mate. Unfortunately, they are not good enough for us. I'm not here to give you any advice, but try to Sell half and Buy more in VALIRX or SAREUM. I believe You will recover your loss there in both, but I don't know which one will come first. Good luck to you Mate. Obelix
Latino they had no intention of buying that's the point. The do it to drive up interest and then bang they issue more shares to their mates heavily discounted that will flood market and does nothing but provide working capital and provide a little return to the big seller leaving Pi screwed over It's a scam
There were many investors here who thought the BioMoti has little revenue and was not a worthwhile aquisition...therefore surely it's good they've withdrawn from this deal than go ahead with it just for the sake of it?
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.